A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
This is a multicenter, open-label study enrolling a total of up to 23 patients.
Metastatic Colorectal Cancer
DRUG: FOLFOX regimen|DRUG: bevacizumab|DRUG: dulanermin
Incidence and nature of dose-limiting toxicities, Until study discontinuation or the end of Cycle 26
Incidence, nature, and severity of adverse events, Until study discontinuation or the end of Cycle 26|Change in vital signs, Until study discontinuation or the end of Cycle 26|Change in clinical laboratory results, Until study discontinuation or the end of Cycle 26|Incidence of anti-dulanermin antibodies, Until study discontinuation or the end of Cycle 26
This is a multicenter, open-label study enrolling a total of up to 23 patients.